Are Americans Investing in Chinese Forced Labor Companies?
The House Select Committee on the CCP published a preliminary report on the use of forced labor in Shein and Temu supply chains. Many Americans are investors.
Details
Supply Chain Crisis, Not Tariffs, Stoked Inflation
Don’t blame the China tariffs on inflation. Supply chain snafus were a much bigger deal, a Federal Reserve report says.
Taiwan Agreement Risks Treasury Rewriting Customs Law Globally
On June 1, 2023, the United States and Taiwan signed “the first agreement under the U.S.-Taiwan Initiative on 21st Century Trade.” “Initiative”? “21st Century Trade”?
Katherine Tai Says Globalization No Longer Sustainable
At National Press Club, Katherine Tai talks about supply chain issues, what ‘de-risking’ from China might look like, and how USTR thinks about it.
CPA Applauds Bicameral Bill Targeting De Minimis, the ‘China Free Trade’ Loophole
The House and Senate join forces to remove China, others, from the duty-free ‘de minimis’ import rule.
CPA Applauds Senators Cassidy, Baldwin and Vance for Bill to Limit Damage of “De Minimis” Import Loophole
Three Senators going after China’s “free trade” deal with the United States.
Congress Should Compel Global Divestment from China’s Slave Labor
Creating a stark choice between American investment and forced labor operations is the best way to combat modern slavery in China. Public opinion of China
CPA Applauds House Bill Seeking to Ban Securities of Foreign Adversaries from Private Pension Plans
The Coalition for a Prosperous America (CPA) today applauded a new bill by Rep. Jim Banks (R-IN-03) that would ban private pension plans from investing
Written Testimony for House Subcommittee on National Security, Illicit Finance, and International Financial Institutions: Dollar Dominance Today and in the Future
Written Testimony for House Committee on Financial Services, Subcommittee on National Security, Illicit Finance, and International Financial Institutions Submitted by Jeff Ferry, Chief Economist, Coalition
FDA Allows Uninspected China Lab to Sell Cancer Drugs in the US
A Chinese cancer drug maker that has not been inspected by the FDA since 2018 is selling chemotherapy drugs to the U.S. due to shortages. When will the U.S. meet its critical medication needs?
